智通财经APP讯，科济药业-B(02171)发布公告，，CT071(一种靶向GPRC5D的自体CAR-T细胞产品)用于治疗新诊断的多发性骨髓瘤(NDMM)的研究者发起的临床试验 (NCT06407947)的研究结果摘要已被2025年欧洲血液学协会“( EHA”)年会接受，将在壁报展示环节进行发布。摘要和进一步信息将于欧洲中部时间2025年5月14 日15:30后公布。
CT071是一款科济药业基于CARcelerateTM专有平台开发的靶向GPRC5D的CAR-T 细胞治疗候选产品，用于治疗复发╱难治多发性骨髓瘤或复发╱难治浆细胞白血病(PCL)。一项研究者发起的临床试验(NCT05838131)正在中国开展，旨在初步评估CT071治疗复发╱难治多发性骨髓瘤或浆细胞白血病的安全性和有效性。另一项研究者发起的试验(NCT06407947)正在中国开展，用于治疗新诊断的多发性骨髓瘤(NDMM)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.